Biotech / Capital raising
Surrozen closes $95.1 million second tranche and extends its expected cash runway into 2029
Gross proceeds before fees came in 3.55% below the approximately $98.6 million committed in March 2025, and the two tranches total approximately $171.5 million. The closing followed FDA clearance of the SZN-8141 IND on October 2, 2026.